'%2F%3E%3Cpath%20d%3D'M11%205H21M13.5%205V11.6A8.5%208.5%200%201%200%2018.5%2011.6V5'%20fill%3D'none'%20stroke%3D'%23fff'%20stroke-width%3D'3.4'%20stroke-linecap%3D'round'%20stroke-linejoin%3D'round'%2F%3E%3Cpath%20d%3D'M10.6%2019.6L13.9%2021.8L17.6%2018.4L21.4%2020.4'%20fill%3D'none'%20stroke%3D'%23fff'%20stroke-width%3D'2.6'%20stroke-linecap%3D'round'%20stroke-linejoin%3D'round'%2F%3E%3Ccircle%20cx%3D'17.6'%20cy%3D'18.4'%20r%3D'2.6'%20fill%3D'%23fff'%2F%3E%3C%2Fsvg%3E){kind=small}
REKVINA LABORATORIES LTD.
VINRKLB (BSE 526075) · ISIN INE092O01028 · Pharmaceuticals · Est. 1988 · listed 1993 · website
ESM Stage 1 · BSE GSM Stage 0 · BSE
In Q1 FY27 (quarter to 30 June 2026, standalone), revenue was ₹0.67 cr and profit after tax −₹0.12 cr.
Open the full company file Every section, filings and your notes, in the app.
Quarterly results
| Quarter | Revenue | Profit after tax | EPS (₹) | Filed |
|---|---|---|---|---|
| Q1 FY27 standalone | ₹0.67 cr | −₹0.12 cr | −0.20 | 13 Aug 2026 |
| Q4 FY26 standalone | ₹0.72 cr | −₹0.06 cr | −0.10 | 21 May 2026 |
| Q3 FY26 standalone | ₹0.35 cr | −₹0.12 cr | −0.21 | 6 Feb 2026 |
| Q2 FY26 standalone | ₹0.2 cr | −₹0.03 cr | 0.06 | 14 Nov 2025 |
| Q1 FY26 standalone | ₹0 cr | −₹0.04 cr | 0.00 | 13 Aug 2025 |
| Q4 FY25 standalone | ₹0 cr | −₹0.04 cr | −0.07 | 30 May 2025 |
Balance sheet
| As of | Total equity | Borrowings | Total assets |
|---|---|---|---|
| 31 Mar 2026 standalone | −₹1.23 cr | ₹1.47 cr | ₹1.19 cr |
| 30 Sep 2025 standalone | −₹0.75 cr | ₹0.81 cr | ₹0.07 cr |
| 31 Mar 2025 standalone | −₹0.34 cr | ₹0.25 cr | ₹0.03 cr |
Shareholding
| Promoter | FII | DII | Public |
|---|---|---|---|
| 77.00% | — | — | 23.00% |
Latest filings
- Annual Report FY2025-26 (New) 3 September 2026 · BSE
- FINANCIAL RESULT QTR1 13 August 2026 · BSE
- OUTCOME OF BOARD MEETING 13 August 2026 · BSE
- Standalone Audited Financial Results for the Quarter ended & Year ended on March 31, 2026 along with statement of Assets & Liabilities, Cash Flow statement & unmodified Audit Report. 21 May 2026 · BSE
- Pursuant to Reg 33 read with Part A of Schedule III of SEBI (LODR) Regulation, 2015, we hereby submitting the following: 1. Standalone Audited Financial Results for the Quarter ended .... 21 May 2026 · BSE
Other companies in Pharmaceuticals
- Lupin Limited
- Sun Pharmaceutical Industries Limited
- Torrent Pharmaceuticals Limited
- Zydus Lifesciences Limited
- Ajanta Pharma Limited
- Alivus Life Sciences Limited
- Wockhardt Limited
- Morepen Laboratories Limited
Figures as filed by the company with NSE and BSE; surveillance status from the exchanges' lists. Updated 30 September 2026.
Information and calculation tools by Rachid Asen. Not investment advice or research. Facts from company filings and the exchanges' lists, for information only; not a recommendation to buy, sell or hold. Verify with the exchange.